Farxiga FDA Approval History
Reviewed by Judith Stewart BPharm. Last updated on May 6, 2020.
Farxiga (dapagliflozin) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated for the treatment of type 2 diabetes mellitus and heart failure.
- Type 2 Diabetes Mellitus
- as an adjunct to diet and exercise to improve glycemic control in adults.
- to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and established cardiovascular disease or multiple cardiovascular risk factors.
- Heart Failure
- to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure with reduced ejection fraction (NYHA class II-IV).
Development Timeline for Farxiga
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.